Sally Gu advises clients on U.S. Food and Drug Administration (FDA) review and life cycle management, compliance with current good manufacturing practices, and advertising and promotion compliance matters.

Sally's practice focuses on issues concerning product development and regulatory exclusivity and FDA regulatory compliance and enforcement. She also advises on FDA regulatory issues arising in corporate transactional matters and filings with the U.S. Securities and Exchange Commission, and issues relating to the regulation of CBD.

While at University of Michigan Law School, Sally was a notes editor for the Michigan Law Review and president of the Michigan Health Law Organization.

In addition to assisting clients in the life sciences and health care industry, Sally is also active in the firm's Pro Bono practice.